Capstan Therapeutics
Latest round
- Series B
Last raised
- Mar 2024
Total raised
- $253M
Investors
- 15
About Capstan Therapeutics
Based in California, US, and founded in 2021, Capstan Therapeutics Inc. operates as a biotech company that provides the development and advancement of vivo cell-based engineering therapies. Based in the US, Capstan Therapeutics Inc. is a biotechnology company that provides the development and advancement of cell-based therapies to treat patients across multiple disease categories like oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. Based in California, US, and founded in 2021, Capstan Therapeutics Inc. operates as a biotech company that provides the development and advancement of vivo cell-based engineering therapies In June 2025, AbbVie agreed to acquire Capstan Therapeutics Inc.1 billion in cash. The company combines vivo cell therapy with genetic medicines to develop new treatment options for patients across oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. Capstan’s precision vivo engineering technology platform is comprised of targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body, non-viral delivery systems, cell type-specific targeting molecules, and disease-specific payload design through in vivo generated CAR T cells. Capstan Therapeutics generates revenue by developing and licensing its proprietary CellSeeker targeted lipid nanoparticle platform, which delivers RNA payloads such as mRNA or gene editing tool to reprogram specific cell types in vivo. This technology enables the creation of off-the-shelf CAR-T therapies and other treatments for autoimmune diseases, oncology, fibrosis, and monogenic blood disorders. The June 2025 acquisition will help the company to accelerate clinical development, expanding resources and enhancing its platform’s reach in autoimmune and cell therapy markets through AbbVie’s global infrastructure.
Who invested in Capstan Therapeutics
15 investors across 3 rounds
See all investors in Capstan Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Capstan Therapeutics
Who invested in Capstan Therapeutics?
Capstan Therapeutics has 15 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Capstan Therapeutics raised?
Capstan Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Capstan Therapeutics last raise money?
Capstan Therapeutics's most recent round on record is a Series B, in Mar 2024.
What does Capstan Therapeutics do?
Based in California, US, and founded in 2021, Capstan Therapeutics Inc.
Where is Capstan Therapeutics headquartered?
Capstan Therapeutics is headquartered in San Diego, US.
Which VCs invest in companies like Capstan Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Capstan Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Capstan Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.